SG11202013220SA - Anhydrous sodium thiosulfate and formulations thereof - Google Patents
Anhydrous sodium thiosulfate and formulations thereofInfo
- Publication number
- SG11202013220SA SG11202013220SA SG11202013220SA SG11202013220SA SG11202013220SA SG 11202013220S A SG11202013220S A SG 11202013220SA SG 11202013220S A SG11202013220S A SG 11202013220SA SG 11202013220S A SG11202013220S A SG 11202013220SA SG 11202013220S A SG11202013220S A SG 11202013220SA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- anhydrous sodium
- sodium thiosulfate
- thiosulfate
- anhydrous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B17/00—Sulfur; Compounds thereof
- C01B17/64—Thiosulfates; Dithionites; Polythionates
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693503P | 2018-07-03 | 2018-07-03 | |
| US201862693502P | 2018-07-03 | 2018-07-03 | |
| PCT/US2019/040051 WO2020009953A1 (en) | 2018-07-03 | 2019-07-01 | Anhydrous sodium thiosulfate and formulations thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013220SA true SG11202013220SA (en) | 2021-01-28 |
Family
ID=69060534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013199UA SG11202013199UA (en) | 2018-07-03 | 2019-07-01 | Formulations of anhydrous sodium thiosulfate |
| SG11202013220SA SG11202013220SA (en) | 2018-07-03 | 2019-07-01 | Anhydrous sodium thiosulfate and formulations thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013199UA SG11202013199UA (en) | 2018-07-03 | 2019-07-01 | Formulations of anhydrous sodium thiosulfate |
Country Status (13)
| Country | Link |
|---|---|
| US (14) | US20200023003A1 (en) |
| EP (2) | EP3818010A4 (en) |
| JP (2) | JP2021530420A (en) |
| KR (2) | KR20210027409A (en) |
| CN (2) | CN112805238A (en) |
| AU (2) | AU2019299217A1 (en) |
| BR (2) | BR112021000021A2 (en) |
| CA (2) | CA3103986A1 (en) |
| IL (2) | IL279857A (en) |
| MA (2) | MA53101A (en) |
| MX (2) | MX2020013734A (en) |
| SG (2) | SG11202013199UA (en) |
| WO (2) | WO2020009954A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7492917B2 (en) | 2018-02-09 | 2024-05-30 | デシベル セラピューティクス インコーポレイテッド | Hypertonic pharmaceutical compositions containing antiplatinum chemoprotectants - Patent Application 20070223333 |
| BR112021000021A2 (en) | 2018-07-03 | 2021-03-30 | Fennec Pharmaceuticals, Inc. | ANhydrous SODIUM THYOSULFATE AND FORMULATIONS OF THE SAME |
| US10813947B1 (en) | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
| CN114848597A (en) * | 2022-07-11 | 2022-08-05 | 北京中科利华医药研究院有限公司 | Sodium thiosulfate injection packaged by double-chamber bag and application |
| CN116062708A (en) * | 2022-12-02 | 2023-05-05 | 东南大学 | Synthetic method of sodium thiosulfate |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB191512599A (en) * | 1915-09-02 | 1916-09-04 | Thomas William Staine Hutchins | Improvements in the Process for the Manufacture of Sodium Thiosulphate. |
| US2635980A (en) * | 1950-02-11 | 1953-04-21 | Wm S Merrell Co | Stabilized sulfa drug |
| GB713559A (en) * | 1951-12-14 | 1954-08-11 | Kodak Ltd | Improvements in the manufacture of the thiosulphates and seleno-sulphates of the alkali metals, calcium and ammonium |
| US2763531A (en) * | 1952-11-29 | 1956-09-18 | Eastman Kodak Co | Manufacture of sodium thiosulphate from sodium sulfite and sulfur in presence of cationic surface active organic bromides |
| DE2851037C2 (en) * | 1978-11-25 | 1980-10-02 | Dr. Franz Koehler Chemie, 6146 Alsbach | Process for the stabilization of sodium thiosulphate solutions intended for medical purposes |
| US4778519A (en) | 1987-02-24 | 1988-10-18 | Batric Pesic | Recovery of precious metals from a thiourea leach |
| AU2001253919B2 (en) | 2000-04-26 | 2006-12-14 | Government Of The United States, D/B/A Department Of Veterans Affairs | Administration of a thiol-based chemoprotectant compound |
| JP5000848B2 (en) * | 2002-05-21 | 2012-08-15 | 第一三共株式会社 | Ghrelin-containing pharmaceutical composition |
| BRPI0413197A (en) * | 2003-08-01 | 2006-10-03 | Amgen Inc | eta wercept crystal; method for making an etanercept crystal; composition; use of an etanercept crystal |
| US20070059382A1 (en) | 2005-09-09 | 2007-03-15 | Board Of Regents, Univ. And Comm. College System Of Nevada... | Medical treatment of breast cancer with boric acid materials |
| US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
| EP2321351B1 (en) * | 2008-08-18 | 2017-11-01 | Pfizer Inc. | Antibodies to ccr2 |
| DK2451435T4 (en) * | 2009-07-08 | 2022-02-28 | Hope Medical Entpr Inc D B A Hope Pharmaceuticals | SODIUM THIOSULPHATE CONTAINING PHARMACEUTICAL COMPOSITIONS |
| WO2013096901A1 (en) * | 2011-12-23 | 2013-06-27 | Mersana Therapeutics, Inc. | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
| JP2015516407A (en) * | 2012-05-10 | 2015-06-11 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Sodium thiosulfate for the treatment of ectopic calcification |
| JP5478680B2 (en) | 2012-08-23 | 2014-04-23 | 小林製薬株式会社 | Stabilizer for composition containing water-soluble polymer thickener |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| BR112016005340A2 (en) | 2013-09-16 | 2017-09-12 | Basf Enzymes Llc | controlled breakdown enzyme formulations |
| CA2927393A1 (en) | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| PT3134131T (en) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Nucleic acid vaccines |
| CN103922292A (en) * | 2014-04-29 | 2014-07-16 | 辽宁石化职业技术学院 | Method for preparing sodium thiosulfate |
| KR20180080189A (en) * | 2015-09-01 | 2018-07-11 | 퍼스트 웨이브 바이오, 인코포레이티드 | And compositions for treating diseases associated with abnormal inflammatory response |
| BR112018006471B1 (en) * | 2015-10-01 | 2024-02-27 | Senomyx, Inc | COMPOUND, COMPOSITION, METHOD OF MODULATING THE MELASTIN MEMBER OF TRANSIENT RECEPTOR POTENTIAL CHANNEL 8 (TRPM8), METHOD OF MODULATING THE FEELING OF REFRESHMENT OF A COMPOSITION, AND METHOD OF INDUCING A FEELING OF REFRESHMENT IN A HUMAN OR ANIMAL |
| WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| ES2751082T3 (en) | 2015-10-30 | 2020-03-30 | Pipeline Therapeutics Inc | Dibenzo azepine compounds and their use in the treatment of ear diseases and disorders |
| US20170087199A1 (en) | 2016-02-10 | 2017-03-30 | Senomyx, Inc. | Compositions for delivering a cooling sensation |
| CA3029281A1 (en) * | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| US20160376263A1 (en) | 2016-07-26 | 2016-12-29 | Senomyx, Inc. | Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof |
| CN107963614A (en) * | 2016-10-20 | 2018-04-27 | 王亚玲 | A kind of quick method for preparing high-purity thiosulfuric acid sodium crystal |
| CN106379867A (en) * | 2016-10-21 | 2017-02-08 | 金川集团股份有限公司 | Method for producing sodium thiosulfate pentahydrate |
| JP7416622B2 (en) | 2017-03-08 | 2024-01-17 | ホープ メディカル エンタープライズ インコーポレイテッド ディー．ビー．エー． ホープ ファーマシューティカルズ | Use of sodium thiosulfate during dialysis |
| MX2019014748A (en) | 2017-06-08 | 2020-08-03 | Eye Therapies Llc | Low-dose brimonidine combinations and uses thereof. |
| US10596190B2 (en) | 2017-11-29 | 2020-03-24 | Oregon Health & Science University | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
| WO2019210107A1 (en) * | 2018-04-25 | 2019-10-31 | Otonomy, Inc. | Otic formulations for drug-induced ototoxicity |
| BR112021000021A2 (en) | 2018-07-03 | 2021-03-30 | Fennec Pharmaceuticals, Inc. | ANhydrous SODIUM THYOSULFATE AND FORMULATIONS OF THE SAME |
| US10813947B1 (en) * | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
-
2019
- 2019-07-01 BR BR112021000021-6A patent/BR112021000021A2/en not_active Application Discontinuation
- 2019-07-01 AU AU2019299217A patent/AU2019299217A1/en active Pending
- 2019-07-01 US US16/458,267 patent/US20200023003A1/en not_active Abandoned
- 2019-07-01 WO PCT/US2019/040052 patent/WO2020009954A1/en active Application Filing
- 2019-07-01 SG SG11202013199UA patent/SG11202013199UA/en unknown
- 2019-07-01 MA MA053101A patent/MA53101A/en unknown
- 2019-07-01 KR KR1020217002827A patent/KR20210027409A/en unknown
- 2019-07-01 CN CN201980044970.2A patent/CN112805238A/en active Pending
- 2019-07-01 CA CA3103986A patent/CA3103986A1/en active Pending
- 2019-07-01 MX MX2020013734A patent/MX2020013734A/en unknown
- 2019-07-01 KR KR1020217002830A patent/KR20210027410A/en unknown
- 2019-07-01 MA MA053102A patent/MA53102A/en unknown
- 2019-07-01 CN CN201980044950.5A patent/CN112805014A/en active Pending
- 2019-07-01 CA CA3103982A patent/CA3103982A1/en active Pending
- 2019-07-01 EP EP19830258.0A patent/EP3818010A4/en not_active Withdrawn
- 2019-07-01 AU AU2019299216A patent/AU2019299216A1/en active Pending
- 2019-07-01 WO PCT/US2019/040051 patent/WO2020009953A1/en active Application Filing
- 2019-07-01 JP JP2020573445A patent/JP2021530420A/en active Pending
- 2019-07-01 MX MX2020013733A patent/MX2020013733A/en unknown
- 2019-07-01 EP EP19830950.2A patent/EP3817751A4/en active Pending
- 2019-07-01 JP JP2020573384A patent/JP2021530462A/en active Pending
- 2019-07-01 US US16/458,261 patent/US10792363B2/en active Active
- 2019-07-01 BR BR112021000022-4A patent/BR112021000022A2/en unknown
- 2019-07-01 SG SG11202013220SA patent/SG11202013220SA/en unknown
-
2020
- 2020-08-28 US US17/005,997 patent/US11291728B2/en active Active
- 2020-12-30 IL IL279857A patent/IL279857A/en unknown
- 2020-12-30 IL IL279856A patent/IL279856A/en unknown
-
2022
- 2022-01-25 US US17/584,257 patent/US20220160875A1/en not_active Abandoned
- 2022-06-24 US US17/849,477 patent/US11510984B2/en active Active
- 2022-07-22 US US17/871,825 patent/US11617793B2/en active Active
- 2022-11-22 US US17/992,707 patent/US11992530B2/en active Active
- 2022-11-22 US US17/992,715 patent/US11964018B2/en active Active
- 2022-11-22 US US17/992,703 patent/US11998604B2/en active Active
-
2023
- 2023-02-20 US US18/111,845 patent/US20230201350A1/en not_active Abandoned
- 2023-02-20 US US18/111,844 patent/US20230201349A1/en not_active Abandoned
- 2023-02-20 US US18/111,849 patent/US20230201351A1/en active Pending
- 2023-09-29 US US18/375,162 patent/US20240042036A1/en active Pending
- 2023-11-06 US US18/503,035 patent/US20240165237A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279857A (en) | Anhydrous sodium thiosulfate and formulations thereof | |
| GB2559774B (en) | Oral cannabinoid formulations | |
| IL280135A (en) | Elagolix sodium compositions and processes | |
| PL3818050T3 (en) | Substituted thiophenecarboxamides and analogues as antibacterials agents | |
| IL295119B1 (en) | Intradialytic use of sodium thiosulfate | |
| IL261777A (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
| ZA202005143B (en) | Oral formulations and uses thereof | |
| GB201809976D0 (en) | Novel formulations | |
| IL277791A (en) | Hsp90-targeting conjugates and formulations thereof | |
| ZA202000490B (en) | Novel secnidazole soft gelatin capsule formulations and uses thereof | |
| SG11202007976WA (en) | Formulations containing mucin-affecting proteases | |
| IL283450A (en) | Capsule formulations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| HUE054988T2 (en) | Oral thyroid therapeutic agent | |
| GB201804545D0 (en) | Formulations | |
| GB201803201D0 (en) | Formulations |